CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010

Author(s): Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, et al.

Abstract

The objective of CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010 is to provide a current comprehensive review of the descriptive epidemiology of primary brain and central nervous system (CNS) tumors in the United States population. The Central Brain Tumor Registry of the United States (CBTRUS) obtained data on all newly diagnosed primary brain and CNS tumors from the Centers for Disease Control and Prevention (CDC), National Program of Cancer Registries (NPCR) and the National Cancer Institute (NCI), Surveillance, Epidemiology and End Results (SEER) program for diagnosis years 2006-2010. Incidence counts and rates of primary malignant and non-malignant brain and CNS tumors are documented by histology, gender, age, race, and Hispanic ethnicity. Mortality and relative survival rates for selected malignant histologies calculated using SEER data for the period 1995-2010 are also presented

Similar Articles

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Author(s): Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al.

Survival and prognosis of patients with astrocytoma with atypical or anaplastic features

Author(s): Nelson D, Nelson J, Davis D, Chang C, Griffins T, et al.

Radium-223 in the treatment of osteoblastic metastases: a critical clinical review

Author(s): Humm JL, Sartor O, Parker C, Bruland OS, Macklis R

Alpha emitter radium-223 and survival in metastatic prostate cancer

Author(s): Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, et al.

Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis

Author(s): Bhattacharyya S, Bhattacharya R, Curley S, McNiven MA, Mukherjee P

Effect of nanoparticle surface charge at the plasma membrane and beyond

Author(s): Arvizo RR, Miranda OR, Thompson MA, Pabelick CM, Bhattacharya R, et al.

Modulating Pharmacokinetics, Tumor Uptake and Biodistribution by Engineered Nanoparticles

Author(s): Arvizo RR, Miranda OR, Moyano DF, Walden CA, Giri K, et al.

Switching the Targeting Pathways of a Therapeutic Antibody by Nanodesign

Author(s): Bhattacharyya S, Singh RD, Pagano R, Robertson JD, Bhattacharya R, et al.

Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors

Author(s): Kennel SJ, Chappell LL, Dadachova K, Brechbiel MW, Lankford TK, et al.

LnPO4 nanoparticles doped with Ac-225 and sequestered daughters for targeted alpha therapy

Author(s): McLaughlin MF, Robertson D, Pevsner PH, Wall JS, Mirzadeh S, et al.

LaPO4 Nanoparticles Doped with Actinium-225 that Partially Sequester Daughter Radionuclides

Author(s): Woodward J, Kennel SJ, Stuckey A, Osborne D, Wall J, et al.

Gold Coated Lanthanide Phosphate Nanoparticles for Targeted Alpha Generator Radiotherapy

Author(s): McLaughlin MF, Woodward J, Boll RA, Wall JS, Rondinone AJ, et al.

Bioelectric effects of intense ultrashort pulses

Author(s): Joshi RP, Schoenbach KH

Nanosecond pulsed electric field thresholds for nanopore formation in neural cells

Author(s): Roth CC, Tolstykh GP, Payne JA, Kuipers MA, Thompson GL